Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ACHV
SellAchieve Life Sciences, Inc. · Healthcare · United States · $817M · Avg Vol: $10M/d
COMPANY DESCRIPTION
Achieve Life Sciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing cytisinicline for the treatment of nicotine addiction. Positioned to address a significant unmet medical need, its proprietary formulation of cytisinicline is in late-stage clinical development. The company is single-asset focused, directing resources towards regulatory approval and subsequent commercialization of its lead candidate.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 38.1M | — |
| EPS | -0.70 | -0.31 | -0.42 | -1.25 | — | -1.66 | -1.37 | -0.64 | — |
| Shares | 102.7M | 102.7M | 102.7M | 53.2M | -48.1% | — | — | — | — |
| Debt | 16.2M | 16.7M | 10.0M | 15.0M | -2.6% | 14.9M | — | — | — |
| Equity | 8.3M | -1.4M | 20.9M | 21.5M | 37.4% | — | — | — | — |
| Op CF | -37.6M | -24.5M | -29.8M | -49.5M | — | -47.0M | — | — | — |
| Inv CF | 0 | -21.0K | -21.6M | 6.1M | — | — | — | — | — |
| Fin CF | 19.3M | 15.3M | 48.5M | 51.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ACHV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ACHV | Achieve Life Sciences, Inc.(you) | $817M | 22 | Sell |
| STTK | Shattuck Labs, Inc. | $793M | 24 | Sell |
| AURA | Aura Biosciences, Inc. | $819M | 25 | Sell |
| ACRS | Aclaris Therapeutics, Inc. | $929M | 23 | Sell |
| GERN | Geron Corporation | $977M | 21 | Sell |
| DRUG | Bright Minds Biosciences Inc. | $756M | 25 | Sell |
| FDMT | 4D Molecular Therapeutics, Inc. | $850M | 26 | Sell |
| NVCT | Nuvectis Pharma, Inc. | $778M | 27 | Sell |
| VSTM | Verastem, Inc. | $621M | 25 | Sell |
| ZURA | Zura Bio Limited | $604M | 20 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%